| Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma. (NCT06732882) | AstraZeneca | 2025-02-27 |
| A Clinical Study of Mass Balance of [14C]HRS-7535 (NCT06819488) | Shandong Suncadia Medicine Co., Ltd. | 2025-02-27 |
| A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants (NCT06846866) | Bristol-Myers Squibb | 2025-02-27 |
| Gene Therapy for Alpha 1- Antitrypsin Deficiency (NCT06996756) | Weill Medical College of Cornell University | 2025-02-26 |
| A Study of Oral E1018 in Healthy Adult Participants (NCT06854042) | Eisai Inc. | 2025-02-26 |
| Safety and Feasibility of Temporal Interference Brain Stimulation for Treatment in Psychiatric Disorders (NCT07179848) | Taipei Veterans General Hospital, Taiwan | 2025-02-26 |
| A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis (NCT07558668) | Sitryx Therapeutics Ltd | 2025-02-26 |
| A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants (NCT06846528) | AstraZeneca | 2025-02-26 |
| AutoSTEA for Adults With Functional Dyspepsia (NCT07020416) | MetroHealth Medical Center | 2025-02-26 |
| Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST) (NCT03895658) | National Institute of Mental Health (NIMH) | 2025-02-26 |
| A Study of HS-20110 in Participants With Advanced Solid Tumors (NCT06892379) | Hansoh BioMedical R&D Company | 2025-02-26 |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (NCT06823167) | Immunome, Inc. | 2025-02-26 |
| A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants (NCT06655194) | Bayer | 2025-02-26 |
| A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (NCT06849791) | AbbVie | 2025-02-26 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects (NCT07098091) | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | 2025-02-26 |
| SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (NCT06873659) | Qurgen Inc. | 2025-02-26 |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors (NCT06792552) | NextCure, Inc. | 2025-02-26 |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (NCT06686394) | Merck Sharp & Dohme LLC | 2025-02-26 |
| UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia (NCT06245746) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-02-26 |
| Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects (NCT07644442) | Hutchmed | 2025-02-26 |
| A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months (NCT07282171) | Comanche Biopharma | 2025-02-26 |
| A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors (NCT06848699) | Shanghai Henlius Biotech | 2025-02-25 |
| Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains (NCT06795451) | University of Cincinnati | 2025-02-25 |
| Intranasal Insulin for Treatment of Alcohol Use Disorder (NCT05988632) | Brown University | 2025-02-25 |
| Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis (NCT07413549) | Beijing Tuohua Weiye Biotechnology Co., Ltd. | 2025-02-25 |
| Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies (NCT06683365) | Craig van Horne, MD, PhD | 2025-02-25 |
| A Phase 1 Study, to Evaluate the Effect of ADV7103 on Gastric pH Under Fed and Fasting Conditions in Adult Healthy Participants. (NCT07446881) | Advicenne Pharma | 2025-02-25 |
| A Phase 1 Mass Balance Study of Varegacestat (NCT06845852) | Immunome, Inc. | 2025-02-25 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML (NCT06563804) | Servier Bio-Innovation LLC | 2025-02-25 |
| Phase IIa Study for IPG11406 in Patients With Lupus Nephritis (NCT06717815) | Nanjing Immunophage Biotech Co., Ltd | 2025-02-25 |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant (NCT06938867) | SNIPR Biome Aps. | 2025-02-25 |
| Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (NCT06820307) | Vertex Pharmaceuticals Incorporated | 2025-02-25 |
| Comparison of Procedural Sedation in TEE (NCT06129188) | University of Alabama at Birmingham | 2025-02-25 |
| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) (NCT06660420) | M.D. Anderson Cancer Center | 2025-02-25 |
| Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants (NCT06753955) | Arialys Therapeutics | 2025-02-25 |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors (NCT06804824) | Vividion Therapeutics, Inc. | 2025-02-25 |
| FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT06609928) | Fred Hutchinson Cancer Center | 2025-02-24 |
| A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors (NCT06730386) | Akeso | 2025-02-24 |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (NCT06741644) | CStone Pharmaceuticals | 2025-02-24 |
| A Cardiac Liability Study of Varegacestat in Healthy Participants (NCT06855264) | Immunome, Inc. | 2025-02-24 |
| EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL (NCT06847204) | Zaeema Kanwal | 2025-02-24 |
| A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1 (NCT06867497) | Boryung Pharmaceutical Co., Ltd | 2025-02-24 |
| Phase I Study of OriC902 in Treatment of Advanced HCC (NCT06891742) | Peking University | 2025-02-24 |
| A PET Study of ENX-104 in Healthy Volunteers (NCT07253272) | Engrail Therapeutics INC | 2025-02-24 |
| Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234 (NCT06845813) | AstraZeneca | 2025-02-24 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (NCT06680128) | SK Bioscience Co., Ltd. | 2025-02-24 |
| Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A (NCT06579144) | Swedish Orphan Biovitrum | 2025-02-24 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis (NCT06617793) | Novartis Pharmaceuticals | 2025-02-24 |
| A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers (NCT07650383) | Energenesis Biomedical Co., Ltd. | 2025-02-24 |
| Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (NCT06745921) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-24 |
| Botox for Chronic Pelvic Pain (NCT06796985) | University of Miami | 2025-02-24 |
| Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) (NCT07197294) | n-Lorem Foundation | 2025-02-24 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (NCT06832982) | Shanghai Pushi Medical Science Co. Ltd | 2025-02-24 |
| A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants (NCT06712082) | Pfizer | 2025-02-24 |
| Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC (NCT06856278) | Zhejiang Provincial People's Hospital | 2025-02-22 |
| Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome (NCT07399535) | Jinnah Postgraduate Medical Centre | 2025-02-22 |
| A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies (NCT06839105) | Shanghai Junshi Bioscience Co., Ltd. | 2025-02-21 |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease (NCT06826612) | Hoffmann-La Roche | 2025-02-21 |
| A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants (NCT06816043) | Merck Sharp & Dohme LLC | 2025-02-21 |
| A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants (NCT06835465) | Genentech, Inc. | 2025-02-21 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease (NCT06732180) | Gain Therapeutics, Inc. | 2025-02-21 |
| Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study (NCT06896747) | Tang-Du Hospital | 2025-02-21 |
| Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants (NCT06738017) | BioMarin Pharmaceutical | 2025-02-21 |
| A Study of AL8326 in Healthy Subjects (NCT07132957) | Advenchen Laboratories Nanjing Ltd. | 2025-02-21 |
| Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NCT06793956) | Sun Yat-sen University | 2025-02-21 |
| CD123-CD16-NK Cells Immunotherapy for AML (NCT06835140) | Chunji Gao | 2025-02-21 |
| Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults (NCT06677918) | EpiEndo Pharmaceuticals | 2025-02-20 |
| Effect of Different Proprioceptive Neuromuscular Facilitation Techniques Versus Flow Trigger Sensitivity on Weaning Off Mechanical Ventilation (NCT06831201) | Beni-Suef University | 2025-02-20 |
| CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Constipation in Adults (NCT06832176) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males (NCT06841926) | Nanjing Zenshine Pharmaceuticals | 2025-02-20 |
| Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors (NCT06787950) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2025-02-20 |
| Oral Metformin for Treating Melasma in Latin American Women (NCT06845540) | University of Puerto Rico | 2025-02-20 |
| SNV4818 in Participants With Advanced Solid Tumors (NCT06736704) | Pikavation Therapeutics, Inc. | 2025-02-20 |
| UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies (NCT06590961) | Ubix Therapeutics, Inc. | 2025-02-20 |
| A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults. (NCT06827457) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-02-20 |
| CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults (NCT06839599) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function (NCT06698549) | Aligos Therapeutics | 2025-02-20 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (NCT06605586) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2025-02-20 |
| A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） (NCT06741098) | Nuwacell Biotechnologies Co., Ltd. | 2025-02-20 |
| CMTS4520 for Chronic Diarrhoea in Adults (NCT06839586) | The Second Hospital of Nanjing Medical University | 2025-02-20 |
| A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC (NCT06926413) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-02-20 |
| CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) (NCT06822881) | Beijing GoBroad Hospital | 2025-02-20 |
| Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus (NCT06852573) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2025-02-20 |
| A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants (NCT06977880) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2025-02-19 |
| NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis (NCT06676631) | Guangdong Provincial People's Hospital | 2025-02-19 |
| Upfront Ruxolitinib for Chronic Graft-vs-host Disease (NCT06695507) | Children's Hospital Medical Center, Cincinnati | 2025-02-19 |
| Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects (NCT06832540) | Hangzhou PhecdaMed Co., Ltd. | 2025-02-19 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma (NCT06843967) | Memorial Sloan Kettering Cancer Center | 2025-02-19 |
| A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (NCT06118515) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-19 |
| A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. (NCT06769984) | Sinocelltech Ltd. | 2025-02-19 |
| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (NCT06703177) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-18 |
| Drug-Drug Interaction Potential of Mavorixafor (NCT06914869) | X4 Pharmaceuticals | 2025-02-18 |
| GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy (NCT06636123) | Virginia Commonwealth University | 2025-02-18 |
| Concurrent Azeliragon With Craniospinal Irradiation (NCT06724926) | NYU Langone Health | 2025-02-18 |
| A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (NCT06834789) | AbbVie | 2025-02-18 |
| An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection (NCT06692179) | University of Minnesota | 2025-02-18 |
| A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias (NCT06466395) | M.D. Anderson Cancer Center | 2025-02-18 |
| A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease (NCT06809400) | Eli Lilly and Company | 2025-02-18 |
| KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (NCT06767046) | Corregene Biotechnology Co., Ltd | 2025-02-18 |
| Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. (NCT06752122) | RNATICS GmbH | 2025-02-18 |